Merck(US:MRK) Benzinga·2025-12-23 19:01Core Insights - Significant investors have adopted a bearish stance on Merck & Co, with 53% of trades being bearish and 46% bullish [1] - The predicted price range for Merck & Co over the last three months is between $90.0 and $110.0 [2] Options Trading Activity - A total of 13 trades were detected for Merck & Co, with 6 puts amounting to $623,040 and 7 calls totaling $278,124 [1] - Noteworthy options activity includes several bearish trades, with significant put options at strike prices of $90.00, $95.00, and $105.00, indicating a bearish sentiment among traders [7] Market Position and Analyst Ratings - Merck & Co's current market position is supported by expert opinions, with an average target price of $119.4 from 5 analysts [9] - Analysts from various firms have differing ratings, with Morgan Stanley maintaining an Equal-Weight rating at $102, while BMO Capital upgraded to Outperform with a target of $130 [10] Company Overview - Merck & Co specializes in pharmaceutical products across various therapeutic areas, including cancer and cardiometabolic diseases, with Keytruda being a major sales contributor [8] - The company generates 47% of its sales from the US human health sector, which includes pharmaceuticals and vaccines [8] Trading Metrics - The trading volume for Merck & Co stands at 7,080,902, with the stock price at $104.99, reflecting a 0.26% increase [12] - The upcoming earnings announcement is expected in 42 days, indicating a potential catalyst for stock movement [12]